Subscribe To

Price Alert Latest News Economic Calendar News

FENC / Fennec Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 6, 2023

RESEARCH TRIANGLE PARK, N.C., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its third quarter 2023 financial results before the opening of the U.S. financial markets on Monday, November 6, 2023. Management will host a conference call and webcast that day to discuss the Company's financial and business results. Read More

Demo Live Account See Partner Details

Content Topics

Fennec

Pharmaceuticals

Report

Third

Quarter

2023

Financial

Results

November

Stock

FENC

Posted: Oct 30 2023, 06:45

Author Name: GlobeNewsWire

FENC News

By GlobeNewsWire
October 30, 2023

Fennec Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 6, 2023

RESEARCH TRIANGLE PARK, N.C., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pha

By GlobeNewsWire
September 7, 2023

Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pha

By Seeking Alpha
August 6, 2023

Fennec Pharmaceuticals Inc. (FENC) Q2 2023 Earnings Call Transcript

Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Robert Andrade - Chief Fina

By GlobeNewsWire
July 31, 2023

Fennec Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 3, 2023

RESEARCH TRIANGLE PARK, N.C., July 31, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pha

By Seeking Alpha
May 13, 2023

Fennec Pharmaceuticals Inc. (FENC) Q1 2023 Earnings Call Transcript

Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Robert Andrade - Chief Financ

By Zacks Investment Research
May 11, 2023

Adherex Technologies Inc. (FENC) Reports Q1 Loss, Misses Revenue Estimates

Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compar

By GlobeNewsWire
May 8, 2023

Fennec Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023

RESEARCH TRIANGLE PARK, N.C., May 08, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty phar

By Zacks Investment Research
March 30, 2023

Adherex Technologies Inc. (FENC) Reports Q4 Loss, Lags Revenue Estimates

Adherex Technologies Inc. (FENC) delivered earnings and revenue surprises of -8.33% and 100%, respectively, for the quarter ended December 2022. Do th

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.